Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein

Pharmaceutical Research

Volumn 16, Issue 3, 1999, Pages 408-414

  Kim, Richard B ^a   Wandel, Christoph ^a   Leake, Brenda ^a   Cvetkovic, Mirjana ^a   Fromm, Martin F ^a   Dempsey, Peter J ^a   Roden, Mark M ^a   Belas, Frank ^a   Chaudhary, Ajai K ^a   Roden, Dan M ^a   Wood, Alastair J J ^a   Wilkinson, Grant R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP3A4; Cytochrome P450; Drug transport; P glycoprotein

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; ENZYME INHIBITOR; ERYTHROMYCIN; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; MEVINOLIN; MIDAZOLAM; NIFEDIPINE; PYRROLE; TERFENADINE;

ANIMAL EXPERIMENT; ARTICLE; CELL LEVEL; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG DISPOSITION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032907322     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1018877803319     Document Type: Article

References (29)

1. 1. F. P. Guengerich. Cychrome P450: Structure, mechanism, and biochemistry, P. R. Ortiz de Montellano. (ed.), Human cytochrome P450 enzymes, Plenum Press, New York, 1995, pp. 473-535.
2. 2. P. Maurel. Cytochromes P450: Metabolic and toxicological aspects, C. Ioannides (ed.), The CYP3 family, CRC Press, Inc., Boca Raton, 1996, pp. 241-270.
3. 3. K. E. Thummel and G. R. Wilkinson. In vitro and in vivo drug interactions involving human CYP3A. Ann. Rev. Pharmacol. Toxicol. 38:389-430 (1998).
4. 4. M. F. Fromm, R. B. Kim, C. M. Stein, G. R. Wilkinson, and D. M. Roden. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99:552-557 (1999).
5. 5. M. M. Gottesman and I. Pastan. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. 62:385-427 (1993).
6. 6. D. Levêque and F. Jehl. P-glycoprotein and pharmacokinetics. Anticancer Res. 15:331-336 (1995).
7. 7. V. J. Wacher, C.-Y. Wu, and L. Z. Benet. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen. 13:129-134 (1995).
8. 8. J. M. Ford and W. N. Hait. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42:155-199 (1990).
9. 9. J. M. Ford. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur. J. Cancer 32A:991-1001 (1996).
10. 10. K. M. Barnes, B. Dickstein, G. B. Cutler, T. Fojo, and S. E. Bates. Steroid transport, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry. 35:4820-4827 (1996).
11. 11. S. Scala, N. Akhmed, U. S. Rao, K. Paull, L.-B. Lan, B. Dickstein, J.-S. Lee, G. H. Elgemeie, W. D. Stein, and S. E. Bates. P-glycoprotein substrates and antagonists cluster into two distinct groups. Mol. Pharmacol. 51:1024-1033 (1997).
12. 12. P. J. Dempsey, K. S. Meise, Y. Yoshitake, K. Nishikawa, and R. J. Coffey. Apical enrichment of human EGF precursor in Madin-Darby canine kidney cells involves preferential basolateral ecto-domain cleavage sensitive to a metalloprotease inhibitor. J. Cell. Biol. 138:747-758 (1997).
13. 13. R. B. Kim, M. F Fromm, C. Wandel, B. Leake, A. J. J. Wood, D. M. Roden, and G. R. Wilkinson. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289-294 (1998).
14. 14. F. P. Guengerich and R. H. Böcker. Cytochrome P-450-catalyzed dehydrogenation of 1,4-dihydropyridines. J. Biol. Chem. 263:8168-8175 (1988).
15. 15. R. G. Knodell, S. D. Hall, G. R. Wilkinson, and F. P. Guengerich. Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J. Pharmacol. Exp. Ther. 241:1112-1119 (1987).
16. 16. R. B. Kim, D. O'Shea, and G. R. Wilkinson. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin. Pharmacol. Ther. 57:645-655 (1995).
17. 17. Y. Caraco, G. R. Wilkinson, and A. J. Wood. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole. Clin. Pharmacol Ther. 60:396-404 (1996).
18. 18. A. K. Chaudhary, F. Belas, S. A. Saleh, C. Wandel, A. J. J. Wood, and I. A. Blair. Quantilation of midazolam and its CYP3A4 metabolites from human plasma using liquid chromalography/tandem mass spectrometry (LC/MS/MS). ISSX Proceedings 10:130(1996).
19. 19. M. Murray. P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease. Clin. Pharmacokinet. 23:132-146 (1992).
20. 20. F. P. Guengerich, M. V. Martin, P. H. Beaune, P. Kremers, T. Wolff, and D. J. Waxman. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261:5051-5060 (1986).
21. 21. J. C. Gorski, S. D. Hall, D. R. Jones, M. VandenBranden, and S. A. Wrighton. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 47:1643-1653 (1994).
22. 22. T. J. Rashid, U. Martin, H. Clarke, D. G. Waller, A. G. Renwick, and C. F. George. Factors affecting the absolute bioavailability of nifedipine. Br. J. Clin. Pharmacol. 40:51-58 (1995).
23. 23. K. E. Thummel, D. O'Shea, M. F. Paine, D. D. Shen, K. L. Kunze, J. D. Perkins, and G. R. Wilkinson. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59:491-502 (1996).
24. 24. J. van Asperen, U. Mayer, O. van Teilingen, and J. H. Beijnen. The functional role of P-glycoprotein in the blood-brain barrier. J. Pharmaceut. Sci. 86:881-884 (1997).
25. 25. C.-H. Yun, R. A. Okerholm, and F. P. Guengerich. Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Met. Disp. 21:403-409 (1993).
26. 26. R. W. Wang, P. H. Kari, A. Y. H. Lu, P. E. Thomas, F. P. Guengerich, and K. P. Vyas. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch. Biochem. Biophys. 290:355-361 (1991).
27. 27. E. G. Schuetz, K. Yasuda, K. Arimori, and J. D. Schuetz. Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene. Arch. Biochem. Biophys. 350:340-347 (1998).
28. 28. P. Chelvan, J. M. T. Hamilton-Miller, and W. Brumfitt. Biliary excretion of erythromycin after parenteral administration. Br. J. Clin. Pharmacol. 8:233-235 (1979).
29. 29. P. B. Watkins. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4: 171-184 (1994).